Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance
Ugarte‐Gil M, Alarcón G, Seet A, Izadi Z, Montgomery A, Duarte‐García A, Gilbert E, Valenzuela‐Almada M, Wise L, Sparks J, Hsu T, D'Silva K, Patel N, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Wallace Z, Jacobsohn L, Strangfeld A, Mateus E, Hyrich K, Gossec L, Carmona L, Lawson‐Tovey S, Kearsley‐Fleet L, Schaefer M, Machado P, Robinson P, Gianfrancesco M, Yazdany J. Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance. Arthritis Care & Research 2022, 75: 53-60. PMID: 36239292, PMCID: PMC9874592, DOI: 10.1002/acr.25039.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusCOVID-19 outcomesRace/ethnicitySevere COVID-19 outcomesSystemic lupus erythematosus patientsImmunosuppressive drug useLupus erythematosus patientsCOVID-19 severityUS general populationLogistic regression modelsOrdinal logistic regression modelsGlucocorticoid doseDisease activityPandemic time periodSD ageLupus erythematosusPossible confoundersSevere outcomesMultivariable modelHigher oddsGeneral populationPatientsDrug useHealth disparitiesOutcome categoriesFactors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Yeoh S, Gianfrancesco M, Lawson-Tovey S, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Schäfer M, Richez C, Hachulla E, Holmqvist M, Scirè C, Lorenz H, Voll R, Hasseli R, Jayatilleke A, Hsu T, D’Silva K, Pimentel-Quiroz V, del Mercado M, Shinjo S, dos Reis Neto E, da Rocha L, de Oliveira e Silva Montandon A, Pons-Estel G, Ornella S, Exeni M, Velozo E, Jordan P, Sirotich E, Hausmann J, Liew J, Jacobsohn L, Gore-Massy M, Sufka P, Grainger R, Bhana S, Wallace Z, Robinson P, Yazdany J, Machado P. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. RMD Open 2022, 8: e002508. PMID: 36100295, PMCID: PMC9471207, DOI: 10.1136/rmdopen-2022-002508.Peer-Reviewed Original ResearchConceptsIdiopathic inflammatory myopathiesSevere COVID-19Prednisolone-equivalent doseHigh disease activityDisease activityInflammatory myopathiesMale sexSevere outcomesCOVID-19Multivariable ordinal logistic regressionOlder ageHigher comorbidity burdenLarge registry dataCOVID-19 diagnosisComorbidity burdenRituximab exposureClinical characteristicsRisk stratificationOrdinal logistic regressionRegistry dataHospitalisationSeverity ScaleDemographic dataLogistic regressionPatientsCharacteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Ugarte-Gil M, Alarcón G, Izadi Z, Duarte-García A, Reátegui-Sokolova C, Clarke A, Wise L, Pons-Estel G, Santos M, Bernatsky S, Ribeiro S, Al Emadi S, Sparks J, Hsu T, Patel N, Gilbert E, Valenzuela-Almada M, Jönsen A, Landolfi G, Fredi M, Goulenok T, Devaux M, Mariette X, Queyrel V, Romão V, Sequeira G, Hasseli R, Hoyer B, Voll R, Specker C, Baez R, Castro-Coello V, Ficco H, Neto E, Ferreira G, Monticielo O, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Costello W, Wallace Z, Jacobsohn L, Taylor T, Ja C, Strangfeld A, Mateus E, Hyrich K, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schäfer M, Machado P, Robinson P, Gianfrancesco M, Yazdany J. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals Of The Rheumatic Diseases 2022, 81: 970-978. PMID: 35172961, PMCID: PMC8882632, DOI: 10.1136/annrheumdis-2021-221636.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusCOVID-19 outcomesSevere outcomesDisease activityLupus erythematosusHigher SLE disease activityActive systemic lupus erythematosusMultivariable ordinal logistic regression modelsSevere COVID-19 outcomesPoor COVID-19 outcomesSLE disease activitySex-adjusted modelsMore severe outcomesCOVID-19 severityCOVID-19Logistic regression modelsOrdinal logistic regression modelsPrednisone doseMale sexGlobal RegistryWorse outcomesMultivariable modelCurrent treatmentComorbiditiesOlder age